BBB National Programs' National Advertising Division (NAD) has recommended that sanofi modify or discontinue several advertising claims for its FDA-approved biologic treatment DUPIXENT, following a challenge filed by Galderma Laboratories, L.P. The ruling, issued on Aug. 05, 2026, impacts how Sanofi communicates the drug's efficacy regarding long-lasting clearer skin, fast itch relief, and a specific prescriber-facing claim about day-2 itch relief. This decision is significant for investors monitoring regulatory scrutiny on pharmaceutical marketing practices and potential operational adjustments in sales strategies.

Galderma, a multinational pharmaceutical company also marketing FDA-approved biologics for moderate-to-severe eczema, challenged various aspects of Sanofi's advertising. The challenges covered DUPIXENT’s mechanism of action, its ability to address inflammation and heal skin from within, its overall efficacy, and claims suggesting it works proactively to keep patients ahead of eczema. The NAD review serves as an independent self-regulation process to ensure advertising truthfulness and fair competition in the U.S. market.

Supported Claims

The NAD found several of Sanofi's challenged claims to be adequately supported by evidence. Specifically, the division upheld claims that DUPIXENT helps patients "stay ahead of eczema," blocks "a key source of inflammation," and can "help heal your skin from within." Additionally, the claim that many adults saw 90% clearer skin was deemed supported without requiring additional disclosure.

The NAD also determined that the challenged advertising did not convey several implied messages alleged by Galderma. These unsupported implications included messages that DUPIXENT prevents eczema progression, blocks the most important source of inflammation, treats nerve inflammation, promises complete healing of eczema-related skin lesions, or is superior to all other FDA-approved eczema treatments.

Recommended Modifications and Discontinuations

Despite supporting core efficacy claims, the NAD recommended modifications to ensure transparency and accuracy in specific contexts:

For the "long-lasting clearer skin" and "fast itch relief" claims, the NAD determined that while Sanofi's evidence supports qualified claims—such as some adults achieving clearer skin at four months and one year, or seeing fast itch relief after the first dose at two weeks—the television advertisements lacked clear and conspicuous disclosures. These disclosures should specify the number of patients who achieved the results or indicate that the results reflected treatment with DUPIXENT used in combination with topical corticosteroids.

Regarding the prescriber-facing claim that DUPIXENT reduced itch "starting as early as day 2," the NAD found that the post hoc analysis relied upon by Sanofi did not support the message of a meaningful treatment benefit beginning that early. Consequently, the division recommended discontinuing or modifying this claim.

Additionally, the NAD separately determined that an animated consumer-facing mechanism-of-action video likely conveyed the unsupported message that inhibition of IL-4 and IL-13 signaling alone is sufficient to address eczema. Although the 90% clearer skin claim itself did not need disclosure, the NAD recommended that if Sanofi continues to present results from one particular study as the basis for the claim in a disclosure, it must use language that does not overstate the supporting evidence or obscure the treatment context.

What the Numbers Show

The NAD's distinction between supported core efficacy claims and unsupported specific timing or mechanism implications highlights a regulatory focus on precise consumer communication. While broad claims about inflammation blocking and skin healing were upheld, specific temporal claims (day-2 relief) and mechanistic simplifications (IL-4/IL-13 alone) faced scrutiny due to insufficient evidentiary support or potential for misleading interpretation. This suggests that future marketing efforts will need to balance efficacy messaging with strict adherence to disclosed clinical contexts, particularly regarding combination therapies.

In its advertiser statement, Sanofi stated that it "will comply with NAD's recommendations." The full text of the decision is available in the BBB National Programs case decision library.

Sanofi India Limited reported a robust second quarter of fiscal year 2026 (Q2FY26), with profit before tax rising 19% year-on-year to ₹1,123 million. This growth underscores the company's strong market position in the diabetes care segment, where its insulin portfolio delivered double-digit growth for the second consecutive quarter, driving margin expansion to 27% from 24% in Q2FY25. Domestic net sales grew by 8% to ₹4,377 million, while total net sales increased by 6%. The results reflect disciplined cost management and a favorable product mix, positioning the company for sustained value creation in the Indian healthcare market.

The Board of Directors approved the unaudited financial results on August 04, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by Price Waterhouse & Co Chartered Accountants LLP, the statutory auditors, who issued a limited review report confirming compliance with applicable accounting standards under Ind AS. Additionally, the Board reconstituted the Stakeholders Relationship Committee and the Risk Management Committee effective October 01, 2026.

Key Financial Metrics

Profit before tax as a percentage of net sales improved to 27% in Q2FY26, up from 24% in Q2FY25. This margin expansion was driven by a favorable product mix and disciplined cost management. Operating expenses, comprising employee costs and other expenses, declined by 5% compared to the second quarter of 2025.

Segment Performance

The insulin portfolio continued its strong trajectory, delivering 14% growth. Sanofi maintains a leadership position in the basal analog market with a 58% value market share and 61% volume market share. Growth was powered by key brands including Lantus®, Toujeo®, and Apidra®, alongside the successful performance of Soliqua®.

The public sector business accelerated significantly, growing by 70%. This surge was attributed to the opening of new accounts for Toujeo® and Soliqua® under the CARE Accounts initiative, strengthening the company's footprint in the diabetes injectable space. Partnership revenues in Cardiovascular, Oral anti-Diabetes, and Central Nervous System segments grew by 2%, while export sales remained broadly stable amid global headwinds.

What the Numbers Show

A notable divergence exists between operating profit growth and working capital movements. While operating expenses declined by 5%, trade receivables surged from ₹1,767 million at the end of FY25 to ₹2,321 million at the end of Q1FY26, an increase of ₹554 million. This suggests potential collection pressure or extended credit terms in the distribution channel, even as cash and cash equivalents rose to ₹3,590 million. The company generated ₹2,114 million in net cash inflow from operating activities during the half-year ended June 30, 2026, down from ₹2,910 million in the same period last year, primarily due to changes in working capital dynamics.

Corporate Governance Updates

The Board also reconstituted two key committees effective October 01, 2026:

• Stakeholders Relationship Committee: Chaired by Independent Director Siraj Chaudhry, with Managing Director Deepak Arora and Whole Time Director Sudipta Chakraborty as members.
• Risk Management Committee: Chaired by Independent Director Rajani Kesari, with members Siraj Chaudhry, Deepak Arora, and Whole Time Director Mahadev Gawade.

Additionally, Rachid Ayari will step down as Whole Time Director and Chief Financial Officer on September 30, 2026. His name will be removed from the list of Key Managerial Personnel authorized to make disclosures to stock exchanges.